2-hydroxy-5-nitro-benzoic acid p-tolyl ester | 55076-28-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 缩酚酸和缩酚酸环醚类
• 英文名称: 2-hydroxy-5-nitro-benzoic acid p-tolyl ester
• 英文别名: p-tolyl 2-hydroxy-5-nitrobenzoate；2-hydroxy-5-nitro-benzoic acid p-tolyl ester；2-Hydroxy-5-nitro-benzoesaeure-p-tolylester；2-Hydroxy-5-nitrobenzoesaeure-(p-tolylester)
• CAS: 55076-28-3
• 化学式: C₁₄H₁₁NO₅
• 分子量: 273.245
• InChiKey: IWNJOVDUUPUBGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.83
• 重原子数：
  20.0
• 可旋转键数：
  3.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  89.67
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  2-hydroxy-5-nitro-benzoic acid p-tolyl ester 、 溴 生成 alkaline earth salt of/the/ methylsulfuric acid
  参考文献：
  名称：

  33 ku protein associated several polypeptides with nearly the same molecular weight but not the same isoelectric point

  摘要：

  The 33 ku protein, prepared from NaCl-treated PS II particles, has shown an single band by SDS-PAGE. After being dialyzed against the low-osmotic medium at 4 degrees C, it has been found that the 33 ku protein degraded into several small fragments. This result suggests that the preparations of 33 ku protein probably contain some latent proteinases. It has also been found, by the 2-D electrophoresis and IEF, that the preparations of 33 ku protein not dialyzed against the tow-osmotic medium contain several polypeptides with nearly the same molecular weight but not the same isoelectric point as the 33 ku protein.

  DOI：

  10.1007/bf02884904
• 作为产物：
  描述：

  2-(4-methylphenoxy)-5-nitrobenzoic acid 在 sodium carbonate 、 10-甲基-9-均三甲苯基吖啶高氯酸盐 作用下， 以 水 、 乙腈 为溶剂， 反应 16.0h， 以56%的产率得到2-hydroxy-5-nitro-benzoic acid p-tolyl ester
  参考文献：
  名称：

  2-芳氧基苯甲酸的光氧化还原中性微笑微笑重排

  摘要：

  我们报告了使用可见光光氧化还原催化的2-芳氧基苯甲酸自由基Smiles重排以获得芳基水杨酸酯。该方法不含贵金属，操作简单，反应可在温和的间歇或流动条件下进行。作为氧化还原中性工艺，不需要化学计量的氧化剂或还原剂。

  DOI：

  10.1039/c7ob02579c

文献信息

• Do Statins Afford Neuroprotection in Patients with Cerebral Ischaemia and Stroke?
  作者：Carl J. Vaughan、Norman Delanty、Craig T. Basson

  DOI：10.2165/00023210-200115080-00002

  日期：——

  An emerging body of evidence indicates that β-hydroxy-β-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or ‘statins’, provide neuroprotection in addition to reducing ischaemic stroke. Statins reduce the incidence of ischaemic stroke by stabilising atherosclerotic plaques in the precerebral vasculature and through antithrombotic actions, and the neuroprotective effects of statins may confer significant clinical benefit. Some of these neuroprotective effects are likely to be cholesterol independent and mediated by the interruption of isoprenoid biosynthesis. Therapy with statins may modulate endothelial function and preserve blood flow to regions exposed to an ischaemic insult. In particular, statin-mediated preservation of endothelial nitric oxide synthase activity in cerebral vasculature, especially in the ischaemic penumbra, may limit neurological deficit. Moreover, putative anti-inflammatory and antioxidant properties of statins may confer additional neuroprotection. Further large clinical trials are necessary to address the role of statin therapy in the primary prevention of stroke, small vessel cerebrovascular disease and vascular dementia.

  越来越多的证据表明，β-羟基-β-甲基戊二酰辅酶 A（HMG-CoA）还原酶抑制剂或 "他汀类药物 "除了能减少缺血性中风外，还能提供神经保护。他汀类药物通过稳定脑前血管中的动脉粥样硬化斑块和抗血栓作用降低缺血性中风的发病率，他汀类药物的神经保护作用可能会带来显著的临床益处。其中一些神经保护作用可能与胆固醇无关，而是通过中断异肾上腺素的生物合成来实现。他汀类药物可调节内皮功能，保护缺血区域的血流。特别是，他汀类药物介导的脑血管内皮一氧化氮合酶活性的保持，尤其是在缺血半影区，可能会限制神经功能的缺失。此外，他汀类药物可能具有的抗炎和抗氧化特性还能提供额外的神经保护作用。他汀类药物在中风、小血管性脑血管病和血管性痴呆的一级预防中的作用还需要进一步的大型临床试验来验证。